Review Article | Open Access
Adnan Erol, "Muscle-Specific PPAR Agonism May Provide Synergistic Benefits with Life Style Modifications", PPAR Research, vol. 2007, Article ID 030578, 7 pages, 2007. https://doi.org/10.1155/2007/30578
Muscle-Specific PPAR Agonism May Provide Synergistic Benefits with Life Style Modifications
Peroxisome proliferator-activated receptor (PPAR) has emerged as a powerful metabolic regulator in diverse tissues including fat, skeletal muscle, and the heart. It is now established that activation of PPAR promotes fatty acid oxidation in several tissues, such as skeletal muscle and adipose tissue. In muscle, PPAR appears to act as a central regulator of fatty acid catabolism. PPAR contents are increased in muscle during physiological situations such as physical exercise or long-term fasting, characterized by increased fatty acid oxidation. Targeted expression of an activated form of PPAR in skeletal muscle induces a switch to form increased numbers of type I muscle fibers resembling the fiber type transition by endurance training. Activation of PPAR also enhances mitochondrial capacity and fat oxidation in the skeletal muscle that resembles the effect of regular exercise. Therefore, it is hypothesized that muscle-specific PPAR agonists could be a key strategy to support the poor cardiorespiratory fitness associated with metabolic disorders.
- C. Gaudel and P. A. Grimaldi, “Metabolic functions of peroxisome proliferator-activated receptor in skeletal muscle,” PPAR Research, vol. 2007, Article ID 86394, 6 pages, 2007.
- Y.-X. Wang, C.-L. Zhang, and R. T. Yu et al., “Regulation of muscle fiber type and running endurance by PPAR,” PLoS Biology, vol. 2, no. 10, pp. 1532–1539, 2004.
- G. D. Barish, V. A. Narkar, and R. M. Evans, “PPAR: a dagger in the heart of the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006.
- C. K. Roberts and R. J. Barnard, “Effects of exercise and diet on chronic disease,” Journal of Applied Physiology, vol. 98, no. 1, pp. 3–30, 2005.
- F. W. Booth and R. A. Shanely, “The biochemical basis of the health effects of exercise: an integrative view,” in Proceedings of the Nutrition Society, vol. 63, no. 2, pp. 199–203, Columbia, Mo, USA, May 2004.
- T. R. Koves, P. Li, and J. An et al., “Peroxisome proliferator-activated receptor- co-activator 1-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency,” Journal of Biological Chemistry, vol. 280, no. 39, pp. 33588–33598, 2005.
- A. P. Russell, J. Feilchenfeldt, and S. Schreiber et al., “Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor- coactivator-1 and peroxisome proliferator-activated receptor- in skeletal muscle,” Diabetes, vol. 52, no. 12, pp. 2874–2881, 2003.
- S. Trappe, M. Harber, and A. Creer et al., “Single muscle fiber adaptations with marathon training,” Journal of Applied Physiology, vol. 101, no. 3, pp. 721–727, 2006.
- E. Volpi, R. Nazemi, and S. Fujita, “Muscle tissue changes with aging,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 7, no. 4, pp. 405–410, 2004.
- D. Freyssenet, “Energy sensing and regulation of gene expression in skeletal muscle,” Journal of Applied Physiology, vol. 102, no. 2, pp. 529–540, 2007.
- A. Leal-Cerro, A. Gippini, and M. J. Amaya et al., “Mechanisms underlying the neuroendocrine response to physical exercise,” Journal of Endocrinological Investigation, vol. 26, no. 9, pp. 879–885, 2003.
- J. Mercier, A. Perez-Martin, X. Bigard, and R. Ventura, “Muscle plasticity and metabolism: effects of exercise and chronic diseases,” Molecular Aspects of Medicine, vol. 20, no. 6, pp. 319–373, 1999.
- A. G. Smith and G. E. O. Muscat, “Skeletal muscle and nuclear hormone receptors: Implications for cardiovascular and metabolic disease,” International Journal of Biochemistry and Cell Biology, vol. 37, no. 10, pp. 2047–2063, 2005.
- D. Pette, H. Peuker, and R. S. Staron, “The impact of biochemical methods for single muscle fibre analysis,” Acta Physiologica Scandinavica, vol. 166, no. 4, pp. 261–277, 1999.
- J. He, S. Watkins, and D. E. Kelley, “Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity,” Diabetes, vol. 50, no. 4, pp. 817–823, 2001.
- J. Norrbom, C. J. Sundberg, H. Ameln, W. E. Kraus, E. Jansson, and T. Gustafsson, “PGC-1 mRNA expression is influenced by metabolic perturbation in exercising human skeletal muscle,” Journal of Applied Physiology, vol. 96, no. 1, pp. 189–194, 2004.
- K. Baar, A. R. Wende, and T. E. Jones et al., “Adaptations of skeletal muscle to exercise: Rapid increase in the transcriptional coactivator PGC-1,” FASEB Journal, vol. 16, no. 14, pp. 1879–1886, 2002.
- S.-H. Koo, H. Satoh, and S. Herzig et al., “PGC-1 promotes insulin resistance in liver through PPAR--dependent induction of TRB-3,” Nature Medicine, vol. 10, no. 5, pp. 530–534, 2004.
- H. Liang and W. F. Ward, “PGC-1: a key regulator of energy metabolism,” Advances in Physiology Education, vol. 30, no. 4, pp. 145–151, 2006.
- E. Hondares, I. Pineda-Torra, R. Iglesias, B. Staels, F. Villarroya, and M. Giralt, “PPAR, but not PPAR, activates PGC-1 gene transcription in muscle,” Biochemical and Biophysical Research Communications, vol. 354, no. 4, pp. 1021–1027, 2007.
- S. Luquet, J. Lopez-Soriano, and D. Holst et al., “Peroxisome proliferator-activated receptor controls muscle development and oxidative capability,” FASEB Journal, vol. 17, no. 15, pp. 2299–2301, 2003.
- P. Garcia-Roves, J. M. Huss, and D.-H. Han et al., “Raising plasma fatty acid concentration induces increased biogenesis of mitochondria in skeletal muscle,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 25, pp. 10709–10713, 2007.
- R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004.
- O. Barbier, I. P. Torra, and Y. Duguay et al., “Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 5, pp. 717–726, 2002.
- S. Luquet, J. Lopez-Soriano, and D. Holst et al., “Roles of peroxisome proliferator-activated receptor delta (PPAR) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome,” Biochimie, vol. 86, no. 11, pp. 833–837, 2004.
- D. M. Muoio, D. B. MacLean, and D. B. Lang et al., “Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) knock-out mice. Evidence for compensatory regulation by PPAR,” Journal of Biological Chemistry, vol. 277, no. 29, pp. 26089–26097, 2002.
- U. Dressel, T. L. Allen, J. B. Pippal, P. R. Rohde, P. Lau, and G. E.O. Muscat, “The peroxisome proliferator-activated receptor agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells,” Molecular Endocrinology, vol. 17, no. 12, pp. 2477–2493, 2003.
- O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996.
- M. Schuler, F. Ali, and C. Chambon et al., “PGC1 expression is controlled in skeletal muscles by PPAR, whose ablation results in fiber-type switching, obesity, and type 2 diabetes,” Cell Metabolism, vol. 4, no. 5, pp. 407–414, 2006.
- Y.-X. Wang, C.-H. Lee, S. Tiep, R. T. Yu, J. Ham, H. Kang, and R. M. Evans, “Peroxisome-proliferator-activated receptor activates fat metabolism to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003.
- E. Barton and C. Morris, “Mechanisms and strategies to counter muscle atrophy,” Journals of Gerontology—Series A Biological Sciences and Medical Sciences, vol. 58, no. 10, pp. 923–926, 2003.
- J. Lexell and D. Downham, “what is the effect of aging on type 2 muscle fiber?,” Journals of Neurol Science, vol. 107, no. 2, pp. 250–251, 1992.
- M. R. Deschenes, “Effects of aging on muscle fiber type and size,” Sports Medicine, vol. 34, no. 12, pp. 809–824, 2004.
- K. E. Conley, S. A. Jubrias, C. E. Amara, and D. J. Marcinek, “Mitochondrial dysfunction: impact on exercise performance and cellular aging,” Exercise and Sport Sciences Reviews, vol. 35, no. 2, pp. 43–49, 2007.
- Z. Arany, N. Lebrasseur, and C. Morris et al., “The transcriptional coactivator PGC-1 drives the formation of oxidative type IIX fibers in skeletal muscle,” Cell Metabolism, vol. 5, no. 1, pp. 35–46, 2007.
- C. Ling, P. Poulsen, and E. Carlsson et al., “Multiple environmental and genetic factors influence skeletal muscle PGC-1 and PGC-1 gene expression in twins,” Journal of Clinical Investigation, vol. 114, no. 10, pp. 1518–1526, 2004.
- Y. Kamei, H. Ohizumi, and Y. Fujitani et al., “PPAR coactivator 1/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12378–12383, 2003.
- A. Oberbach, Y. Bossenz, and S. Lehmann et al., “Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes,” Diabetes Care, vol. 29, no. 4, pp. 895–900, 2006.
- G. E. O. Muscat and U. Dressel, “Cardiovascular disease and PPAR: targeting the risk factors,” Current Opinion in Investigational Drugs, vol. 6, no. 9, pp. 887–894, 2005.
- L. Cheng, G. Ding, and Q. Qin et al., “Cardiomyocyte-restricted peroxisome proliferator-activated receptor- deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy,” Nature Medicine, vol. 10, no. 11, pp. 1245–1250, 2004.
- A. Planavila, R. Rodríguez-Calvo, M. Jové, L. Michalik, W. Wahli, J. C. Laguna, and M. Vázquez-Carrera, “Peroxisome proliferator-activated receptor activation inhibits hypertrophy in neonatal rat cardiomyocytes,” Cardiovascular Research, vol. 65, no. 4, pp. 832–841, 2005.
- T. Takahashi, T. Tanaka, and J. Sakai, “New therapeutic target for metabolic syndrome: PPAR,” Endocrine Journal, vol. 54, no. 3, pp. 347–357, 2007.
- T. Tanaka, S. Yamamoto, and H. Iwasaki et al., “Activation of peroxisome proliferator-activated receptor induces fatty acid -oxidation in skeletal muscle and attenuates metabolic syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15924–15929, 2003.
- K. C. Choi, S. Y. Lee, and H. J. Yoo et al., “Effect of PPAR- agonist on the expression of visfatin, adiponectin, and resistin in rat adipose tissue and 3T3-L1 adipocytes,” Biochemical and Biophysical Research Communications, vol. 357, no. 1, pp. 62–67, 2007.
- C. Fürnsinn, T. M. Willson, and B. Brunmair, “Peroxisome proliferator-activated receptor-, a regulator of oxidative capacity, fuel switching and cholesterol transport,” Diabetologia, vol. 50, no. 1, pp. 8–17, 2007.
- U. Seedorf and J. Aberle, “Emerging roles of PPAR in metabolism,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1771, no. 9, pp. 1125–1131, 2007.
- Y. Barak, D. Liao, and W. He et al., “Effects of peroxisome proliferator-activated receptor on placentation, adiposity, and colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 1, pp. 303–308, 2002.
- M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters, “The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR),” Toxicological Sciences, vol. 90, no. 2, pp. 269–295, 2006.
- T.-C. He, T. A. Chan, B. Vogelstein, and K. W. Kinzler, “PPAR is an APC-regulated target of nonsteroidal anti-inflammatory drugs,” Cell, vol. 99, no. 3, pp. 335–345, 1999.
- B. H. Park, B. Vogelstein, and K. W. Kinzler, “Genetic disruption of PPAR decreases the tumorigenicity of human colon cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2598–2603, 2001.
- F. S. Harman, C. J. Nicol, H. E. Marin, J. M. Ward, F. J. Gonzalez, and J. M. Peters, “Peroxisome proliferator-activated receptor- attenuates colon carcinogenesis,” Nature Medicine, vol. 10, no. 5, pp. 481–483, 2004.
- H. E. Marin, M. A. Peraza, and A. N. Billin et al., “Activation of peroxisome proliferator-activated receptor inhibits colon carcinogenesis,” Cancer Research, vol. 66, no. 8, pp. 4394–4401, 2006.
- R. L. Stephen, M. C. U. Gustafsson, and M. Jarvis et al., “Activation of peroxisome proliferator-activated receptor stimulates the proliferation of human breast and prostate cancer cell lines,” Cancer Research, vol. 64, no. 9, pp. 3162–3170, 2004.
- L. Xu, C. Han, and T. Wu, “A novel positive feedback loop between peroxisome proliferator-activated receptor- and prostaglandin signaling pathways for human cholangiocarcinoma cell growth,” Journal of Biological Chemistry, vol. 281, no. 45, pp. 33982–33996, 2006.
- A. Erol, “Insulin resistance is an evolutionarily conserved physiological mechanism at the cellular level for protection against increased oxidative stress,” BioEssays, vol. 29, no. 8, pp. 811–818, 2007.
Copyright © 2007 Adnan Erol. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.